Atossa Therapeutics Inc (ATOS)
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology medicines for areas of significant unmet medical need in the United States. The company’s lead candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader that is in Phase 2 clinical development for the treatment of breast cancer and for reducing breast cancer risk. Atossa Therapeutics was founded in 2008, formerly operated as Atossa Genetics Inc., and adopted its current name in January 2020. The company is headquartered in Seattle, Washington, and its common stock trades on NASDAQ under the ticker ATOS.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ATOS
|
$2.57
|
13.7% Upside
|
Fair
|
$18.67
|
726.0% Upside
|
Bargain
|
Weak
|
0.0%
|
November 16, 2026
|
0.8x
|
22.553 M
|
-3.541 M
|
0.0%
|
99.7%
|
-21.3
|
94.9%
|
